Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro

Xiao,Wei; Gao,Zhiyong; Duan,Yixing; Yuan,Wuxiong; Ke,Yang

doi:10.3892/or.2015.4041

Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro

Authors:
- Wei Xiao
- Zhiyong Gao
- Yixing Duan
- Wuxiong Yuan
- Yang Ke
View Affiliations

Affiliations: Department of Urology, Hunan Provincial People's Hospital, Changsha, Hunan 410005, P.R. China
Published online on: June 8, 2015 https://doi.org/10.3892/or.2015.4041
Pages: 739-746

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis seriously affects the clinical outcome of renal cell carcinoma patients. Despite the approval of several targeted therapies that have led to an improvement in the progression-free survival rate for these patients, advanced and metastatic renal cell carcinoma remains difficult to treat. Recently, microRNAs have been found to play a critical role in the metastatic dissemination of renal cell carcinoma cells. In the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments. In addition, the results were confirmed in renal carcinoma cell lines. miR-19a expression in the cell lines derived from a metastatic site was higher than that in cell lines derived from a primary site. By gain- and loss-of-function experiments, we found that miR-19a acted as an oncogenic miRNA regulating renal cancer cell proliferation, migration and invasion by directly targeting PIK3CA. Furthermore, we also explored the downstream molecules of miR-19a/PIK3CA signaling. We found that Notch signaling was induced by upregulation of miR-19a, and inactivation of Notch signaling attenuated the cell proliferation, migration and invasion promoted by miR-19a. Thus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.

View Figures

View References

1	Dias F, Teixeira AL, Santos JI, Gomes M, Nogueira A, Assis J and Medeiros R: Renal cell carcinoma development and miRNAs: A possible link to the EGFR pathway. Pharmacogenomics. 14:1793–1803. 2013. View Article : Google Scholar : PubMed/NCBI
2	Redova M, Svoboda M and Slaby O: MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
3	Mishra PJ: MicroRNAs as promising biomarkers in cancer diagnostics. Biomark Res. 2:192014. View Article : Google Scholar : PubMed/NCBI
4	Hao JF, Ren KM, Bai JX, Wang SN, Shao B, Cao N and Li X: Identification of potential biomarkers for clear cell renal cell carcinoma based on microRNA-mRNA pathway relationships. J Cancer Res Ther. 10(Suppl): C167–C177. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhang L, Xul B, Chen S, Lu K, Liu C, Wang Y, Zhao Y, Zhang X, Liu D and Chen M: The complex roles of microRNAs in the metastasis of renal cell carcinoma. J Nanosci Nanotechnol. 13:3195–3203. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lu W, Xu Z, Zhang M and Zuo Y: MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. Int J Clin Exp Pathol. 7:7286–7296. 2014.PubMed/NCBI
7	Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P and Yu Z: miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014. View Article : Google Scholar : PubMed/NCBI
8	Jia Z, Wang K, Zhang A, Wang G, Kang C, Han L and Pu P: miR-19a and miR-19b overexpression in gliomas. Pathol Oncol Res. 19:847–853. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, et al: Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 136:1835–1844. 2014. View Article : Google Scholar : PubMed/NCBI
10	Li X, Xie W, Xie C, Huang C, Zhu J, Liang Z, Deng F, Zhu M, Zhu W, Wu R, et al: Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res. 28:1553–1560. 2014. View Article : Google Scholar : PubMed/NCBI
11	Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, et al: Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: Identification in human tumors and confirmation in animal models. Cancer Res. 69:8256–8264. 2009. View Article : Google Scholar : PubMed/NCBI
12	Vranić S, Bilalović N, Lee LM, Kruslin B, Lilleberg SL and Gatalica Z: PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. Hum Pathol. 38:1425–1431. 2007. View Article : Google Scholar
13	Fujiki K, Inamura H and Matsuoka M: Detrimental effects of Notch1 signaling activated by cadmium in renal proximal tubular epithelial cells. Cell Death Dis. 5:e13782014. View Article : Google Scholar : PubMed/NCBI
14	Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang C, Zhu M, Zhang Y, Wang B, Ni D, et al: High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS One. 7:e350222012. View Article : Google Scholar : PubMed/NCBI
15	Zhang T, Han G, Wang Y, Chen K and Sun Y: MicroRNA expression profiles in supraglottic carcinoma. Oncol Rep. 31:2029–2034. 2014.PubMed/NCBI
16	Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, Zhang Y, Shi Y, Xia X, Wang S, et al: Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. Epub ahead of print. Aug 18–2014.PubMed/NCBI
17	Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, Pospisil V and Stopka T: Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 14:4482014. View Article : Google Scholar : PubMed/NCBI
18	Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, et al: Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 345:216–220. 2014. View Article : Google Scholar : PubMed/NCBI
19	Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, et al: RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 121:1195–1203. 2014. View Article : Google Scholar : PubMed/NCBI
20	Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T, Fellowes A, Dobrovic A, et al kConFab Investigators: Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. Br J Cancer. 111:2351–2360. 2014. View Article : Google Scholar : PubMed/NCBI
21	Tian L, Fang YX, Xue JL and Chen JZ: Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One. 8:e758852013. View Article : Google Scholar : PubMed/NCBI
22	Yu QQ, Wu H, Huang X, Shen H, Shu YQ, Zhang B, Xiang CC, Yu SM, Guo RH and Chen L: MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother. 68:155–161. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wang Y, Tang Q, Li M, Jiang S and Wang X: MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem Biophys Res Commun. 444:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
24	Xiao W, Chen X and He M: Inhibition of the Jagged/Notch pathway inhibits retinoblastoma cell proliferation via suppressing the PI3K/Akt, Src, p38MAPK and Wnt/β-catenin signaling pathways. Mol Med Rep. 10:453–458. 2014.PubMed/NCBI
25	Sato A, Nagase H, Obinata D, Fujiwara K, Fukuda N, Soma M, Yamaguchi K, Kawata N and Takahashi S: Inhibition of MMP-9 using a pyrroleimidazole polyamide reduces cell invasion in renal cell carcinoma. Int J Oncol. 43:1441–1446. 2013.PubMed/NCBI
26	Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, Choi YD, Hong SJ and Cho SH: Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol. 44:560–566. 2003. View Article : Google Scholar : PubMed/NCBI
27	Liang L, Li L, Zeng J, Gao Y, Chen YL, Wang ZQ, Wang XY, Chang LS and He D: Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep. 28:999–1005. 2012.PubMed/NCBI
28	Li D, Masiero M, Banham AH and Harris AL: The notch ligand JAGGED1 as a target for anti-tumor therapy. Front Oncol. 4:2542014. View Article : Google Scholar : PubMed/NCBI
29	Murea M, Park JK, Sharma S, Kato H, Gruenwald A, Niranjan T, Si H, Thomas DB, Pullman JM, Melamed ML, et al: Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int. 78:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
30	Leong KG and Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood. 107:2223–2233. 2006. View Article : Google Scholar
31	Wu K, Zhang L, Lin Y, Yang K and Cheng Y: Inhibition of γ-secretase induces G2/M arrest and triggers apoptosis in renal cell carcinoma. Oncol Lett. 8:55–61. 2014.PubMed/NCBI